RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 Cardiogenic Shock: Limitations of Current Device and Drug Treatment
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 14
IS 16
SP 12
OP 13
DO 10.1177/155989771416008
UL http://mdc.sagepub.com/content/14/16/12.abstract
AB The rate of mortality after cardiogenic shock remains high. However, mortality is not reduced with the currently available devices that provide hemodynamic support. The benefit with inotropic drug therapy is also limited. As the technology evolves, it is anticipated the management of cardiogenic shock will improve, but better identification of patients to benefit is needed.